ALAB vs. KNSA
ALAB (Astera Labs, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. ALAB operates in Semiconductors (Technology), while KNSA operates in Biotechnology (Healthcare). Over the past year, ALAB returned 127.62% vs 145.67% for KNSA. Their 0.09 correlation means their historical movements had little consistent relationship.
Performance
ALAB vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALAB achieves a 87.08% return, which is significantly higher than KNSA's 80.22% return.
ALAB
- 1D
- 3.85%
- 1M
- -27.77%
- 6M
- 106.63%
- YTD
- 87.08%
- 1Y
- 127.62%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 112.28%
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $1.26B | $1.54B | $1.91B | |
| $68.75M | $54.52M | $46.86M |
ALAB vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ALAB Astera Labs, Inc. | 87.08% | 25.60% | 152.00% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 0.41% |
Correlation
The correlation between ALAB and KNSA is -0.00, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.00 |
Correlation (All Time) Calculated using the full available price history since Mar 20, 2024 | 0.09 |
Fundamentals
ALAB:
$53.35B
KNSA:
$5.67B
ALAB:
$1.48
KNSA:
$1.00
ALAB:
210.48
KNSA:
74.38
ALAB:
56.25
KNSA:
7.14
ALAB:
37.74
KNSA:
9.48
ALAB:
$1.00B
KNSA:
$840.85M
ALAB:
$760.99M
KNSA:
$546.22M
ALAB:
$253.12M
KNSA:
$111.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALAB vs. KNSA — Risk / Return Rank
ALAB
KNSA
ALAB vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Astera Labs, Inc. (ALAB) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALAB | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.67 | ||
| Sortino ratioReturn per unit of downside risk | -2.12 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.52 | -0.26 |
| Calmar ratioReturn relative to maximum drawdown | 2.13 | 6.94 | -4.81 |
| Martin ratioReturn relative to average drawdown | 4.03 | 24.13 | -20.10 |
Loading charts...
Drawdowns
ALAB vs. KNSA - Drawdown Comparison
The maximum ALAB drawdown since its inception was -63.69%, smaller than the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for ALAB and KNSA.
Loading charts...
Drawdown Indicators
| ALAB | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.69% | -83.06% | +19.37% |
Max Drawdown (1Y)Largest decline over 1 year | -60.19% | -21.12% | -39.07% |
Max Drawdown (3Y)Largest decline over 3 years | — | -34.14% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -53.17% | — |
Current DrawdownCurrent decline from peak | -35.57% | -8.13% | -27.44% |
Average DrawdownAverage peak-to-trough decline | -29.00% | -40.09% | +11.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.79% | 6.06% | +25.73% |
Volatility
ALAB vs. KNSA - Volatility Comparison
Astera Labs, Inc. (ALAB) has a higher volatility of 34.17% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 26.47%. This indicates that ALAB's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALAB | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 34.17% | 26.47% | +7.70% |
Volatility (6M)Calculated over the trailing 6-month period | 77.73% | 41.55% | +36.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 100.79% | 49.77% | +51.02% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 95.32% | 54.77% | +40.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.32% | 64.34% | +30.98% |
Dividends
ALAB vs. KNSA - Dividend Comparison
Neither ALAB nor KNSA has paid dividends to shareholders.
Financials
ALAB vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Astera Labs, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ALAB vs. KNSA - Profitability Comparison
ALAB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Astera Labs, Inc. reported a gross profit of 235.14M and revenue of 308.36M. Therefore, the gross margin over that period was 76.3%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
ALAB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Astera Labs, Inc. reported an operating income of 61.83M and revenue of 308.36M, resulting in an operating margin of 20.1%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
ALAB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Astera Labs, Inc. reported a net income of 80.31M and revenue of 308.36M, resulting in a net margin of 26.0%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
Frequently Asked Questions
ALAB and KNSA have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALAB has higher volatility (34.17%) compared to KNSA (26.47%). In terms of maximum drawdown, ALAB dropped -63.69% vs KNSA's -83.06%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 1.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALAB and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer